Financial PerformanceZimmer Biomet's earnings leverage is anticipated to be limited, with potential mergers and acquisitions possibly diluting earnings, posing additional challenges to earnings growth.
Guidance ConcernsInvestor confidence may be wavering as concerns mount over Zimmer Biomet's ambitious sales growth target of 5-6% for 2024, particularly following a slower-than-expected growth in U.S. Ortho.
Market ShareZimmer Biomet's global reconstruction market share is declining, with both its global knee and hip shares experiencing a downturn.